Mood stabilizers

Nickel Rock Completes Property Expansion Targeting Lithium Clay Deposits at Silver Peak, Clayton Valley, Nevada

Retrieved on:

Tuesday, January 26, 2021

Physical sciences, Chemistry, Natural sciences, Lithium, Mood stabilizers, Outcrop

The clay layers encountered in these wells are beneath gravel and alluvial cover and do not form obvious outcrops.

Key Points:

The clay layers encountered in these wells are beneath gravel and alluvial cover and do not form obvious outcrops.
This includes Silver Peak, a site uniquely positioned as the only lithium-producing resource in the United States," said Eric Norris, Albemarle President, Lithium.
Robert Setter, President & CEO recently commented "It is apparent that lithium extraction in Clayton Valley from both lithium brine and lithium clays is fast becoming a reality and Nickel Rock needs to be part of that reality.
Nickel Rock plans are to explore the combined property with geologic mapping, rock chip sampling, and exploratory drilling evaluations.

Livent Announces Date for Fourth Quarter 2020 Earnings Release and Webcast Conference Call

Retrieved on:

Monday, January 25, 2021

Chemistry, Physical sciences, Natural sciences, Chemical elements, Reducing agents, Lithium, Mood stabilizers, Boron, Khoros, LLC

For nearly eight decades, Livent has partnered with its customers to safely and sustainably use lithium to power the world.

Key Points:

For nearly eight decades, Livent has partnered with its customers to safely and sustainably use lithium to power the world.
Livent is one of only a small number of companies with the capability, reputation, and know-how to produce high-quality finished lithium compounds that are helping meet the growing demand for lithium.
The company has one of the broadest product portfolios in the industry, powering demand for green energy, modern mobility, the mobile economy, and specialized innovations, including light alloys and lubricants.
Livent employs approximately 800 people throughout the world and operates manufacturing sites in the United States, England, India, China and Argentina.

Newron Completes Enrollment of Explanatory Safety and Efficacy Study With Evenamide in Schizophrenia Patients

Retrieved on:

Thursday, January 21, 2021

Enrollment to the study has been completed with 138 patients randomized to treatment with placebo, 7.5 mg BID, or 15 mg BID of evenamide at study centers in the United States and India.

Key Points:

Enrollment to the study has been completed with 138 patients randomized to treatment with placebo, 7.5 mg BID, or 15 mg BID of evenamide at study centers in the United States and India.
The proposed phase III clinical trial program with evenamide targets patients with schizophrenia experiencing worsening of psychosis on atypical antipsychotics, and treatment-resistant patients not responding to clozapine.
Evenamide has the potential to be first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.
Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

DGAP-News: Newron completes enrollment of explanatory safety and efficacy study with evenamide in schizophrenia patients

Retrieved on:

Thursday, January 21, 2021

Psychiatry, Receptor antagonists, Drugs, Dopamine antagonists, Psychopathology, Atypical antipsychotics, Mood stabilizers, Antipsychotic, Psychosis, Clozapine, Schizophrenia, Typical antipsychotic, evenamide, Newron Pharmaceuticals

Enrollment to the study has been completed with 138 patients randomized to treatment with placebo, 7.5 mg BID, or 15 mg BID of evenamide at study centers in the United States and India.

Key Points:

Enrollment to the study has been completed with 138 patients randomized to treatment with placebo, 7.5 mg BID, or 15 mg BID of evenamide at study centers in the United States and India.
The proposed phase III clinical trial program with evenamide targets patients with schizophrenia experiencing worsening of psychosis on atypical antipsychotics, and treatment-resistant patients not responding to clozapine.
Evenamide has the potential to be first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.
Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

American Lithium Comments on Recent Promotional Activity

Retrieved on:

Saturday, January 16, 2021

Chemistry, Physical sciences, Natural sciences, OTC Markets Group, Mood stabilizers, Lithium

VANCOUVER, British Columbia, Jan. 15, 2021 (GLOBE NEWSWIRE) -- American Lithium Corp. (TSXV: LI) (OTCQB: LIACF) (Frankfurt: 5LA1) (American Lithium or the Company) has been requested by OTC Markets Group Inc. (OTC Markets) to comment on recent promotional activity concerning its common shares traded on the OTCQB.

Key Points:

VANCOUVER, British Columbia, Jan. 15, 2021 (GLOBE NEWSWIRE) -- American Lithium Corp. (TSXV: LI) (OTCQB: LIACF) (Frankfurt: 5LA1) (American Lithium or the Company) has been requested by OTC Markets Group Inc. (OTC Markets) to comment on recent promotional activity concerning its common shares traded on the OTCQB.
The Company has been advised by OTC Markets that OTC Markets takes the position that aspects of the statements were overly promotional.
American Lithium is actively engaged in the acquisition, exploration and development lithium deposits within mining-friendly jurisdictions throughout the Americas.
The Company is currently exploring and developing the TLC lithium project located in the highly prospective Esmeralda lithium district in Nevada.

Cruz Cobalt Joins the Clayton Valley Lithium Advisory Committee

Retrieved on:

Thursday, January 14, 2021

Chemistry, Physical sciences, Natural sciences, Mood stabilizers, Lithium, Clayton Valley, Thacker Pass lithium deposit

Vancouver, British Columbia--(Newsfile Corp. - January 14, 2021) - Cruz Cobalt Corp. (CSE: CRUZ) (OTC PINK: BKTPF) (FSE: A2DMG8) ("Cruz" or the "Company") is pleased to announce that the Company has joined the Clayton Valley Lithium Advisory Committee (the "CVLAC").

Key Points:

Vancouver, British Columbia--(Newsfile Corp. - January 14, 2021) - Cruz Cobalt Corp. (CSE: CRUZ) (OTC PINK: BKTPF) (FSE: A2DMG8) ("Cruz" or the "Company") is pleased to announce that the Company has joined the Clayton Valley Lithium Advisory Committee (the "CVLAC").
The CVLAC is open to, and consists of, individuals and companies that each have a vested interest in the development of lithium assets within the Clayton Valley of Nevada.
The vision of the CVLAC is the collaboration of its members towards development, data, possible mergers and acquisitions and all relevant dealings within the Clayton Valley regarding lithium.
On January 7th, 2021, Albemarle Corp (ALB-NYSE) announced their plan to 'expand capacity at the company's lithium production facility at Silver Peak in Clayton Valley, Nevada.'

Alpha Lithium Provides Drilling Update For Tolillar Lithium Project in Argentina

Retrieved on:

Tuesday, January 12, 2021

Chemistry, Physical sciences, Natural sciences, Chemical elements, Salts, Mood stabilizers, Lithium, Brine, Salar, Cobalt, Oil well

This is an important first step towards the extraction and processing of brine from Alphas 100% owned, 27,500-hectare Tolillar Salar.

Key Points:

This is an important first step towards the extraction and processing of brine from Alphas 100% owned, 27,500-hectare Tolillar Salar.
The primary objective for these two wells is to confirm lithium grades and further refine the Companys hydrogeological model.
Previous drilling and sampling at the Tolillar Salar yielded lithium concentrations of up to 504 mg/L (see press release dated May 5, 2020 ).
Mr. Rosko has extensive experience in salar environments and has been a qualified person on many lithium brine projects.

Piedmont Lithium Announces Strategic Investment in Quebec Hard-Rock Lithium Developer Sayona Mining

Retrieved on:

Monday, January 11, 2021

Piedmont Lithium Limited (Piedmont or Company) is pleased to announce that it has entered into agreements (Agreements) to establish a strategic partnership with Sayona Mining Limited (Sayona) (ASX:SYA) through the purchase of equity stakes in Sayona and its 100% owned Quebec subsidiary, Sayona Quebec Inc (Sayona Quebec), as well as a binding supply agreement for at least 50% of Sayona Quebecs planned spodumene concentrate production.

Key Points:

Piedmont Lithium Limited (Piedmont or Company) is pleased to announce that it has entered into agreements (Agreements) to establish a strategic partnership with Sayona Mining Limited (Sayona) (ASX:SYA) through the purchase of equity stakes in Sayona and its 100% owned Quebec subsidiary, Sayona Quebec Inc (Sayona Quebec), as well as a binding supply agreement for at least 50% of Sayona Quebecs planned spodumene concentrate production.
Piedmont will also purchase a 25.0% stake in Sayona Quebec for approximately US$5.0 million in cash (Project Investment).
Sayona Quebec owns the DFS-level Authier lithium project, the highly prospective Tansim lithium project, and is pursuing a bid to acquire Quebec-based North American Lithiums (NAL) assets.
Piedmont and Sayona Quebec have also entered into a binding spodumene concentrate (SC6) supply agreement (Supply Agreement) pursuant to which Sayona Quebec will supply to Piedmont the greater of 60,000 t/y or 50% of Sayona Quebecs SC6 production at market prices on a life-of-mine basis.

Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia

Retrieved on:

Thursday, January 7, 2021

The results of the RISE study are promising and point to the potential for risperidone to be a subcutaneously administered treatment option for patients with schizophrenia.

Key Points:

The results of the RISE study are promising and point to the potential for risperidone to be a subcutaneously administered treatment option for patients with schizophrenia.
The extended-release subcutaneous risperidone injection is an investigational once-monthly or once-every-two-months injectable formulation of the well-characterized and widely used atypical antipsychotic risperidone for the treatment of schizophrenia.
The investigational subcutaneous risperidone injection utilizes a novel polymer delivery platform that allows the product to be delivered subcutaneously.
544 patients were randomized to receive a subcutaneous injection of risperidone either q1M or q2M, or placebo in a 1:1:1 ratio.

Albemarle Announces Expansion of Nevada Site to Increase Domestic Production of Lithium

Retrieved on:

Thursday, January 7, 2021

Chemistry, Physical sciences, Natural sciences, Lithium, Mood stabilizers, Greenbushes mine, Lithium as an investment

Albemarle's investment in Silver Peak, which produces lithium from brine extracted from the Clayton Valley basin, will support this increased demand for domestic supply of lithium.

Key Points:

Albemarle's investment in Silver Peak, which produces lithium from brine extracted from the Clayton Valley basin, will support this increased demand for domestic supply of lithium.
Beginning in 2021, the company plans to invest $30 million to $50 million to double the current production at the Nevada site by 2025, making full use of its brine water rights.
"As a leader in the lithium industry, our priority is to optimize our world-class resources and production.
This includes Silver Peak, a site uniquely positioned as the only lithium-producing resource in the United States," said Eric Norris, Albemarle President, Lithium.